Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 10/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26598622 | 0.77 | HCRTR1 (0.39) | PDK2HCRTR1HCRTR2FFAR1FEN1 | |
| SCHEMBL15327008 | 0.76 | HCRTR1 (0.46) | PDK2HCRTR1HCRTR2NAMPT | |
| SCHEMBL20539449 | 0.75 | PKM (0.46) | — | |
| SCHEMBL15924834 | 0.74 | CREBBP (0.49) | PDK2 | |
| SCHEMBL15327002 | 0.72 | HCRTR1 (0.63) | PDK2HCRTR1HCRTR2NAMPT | |
| SCHEMBL3848418 | 0.72 | PDK2 (0.47) | PDK2FFAR1FEN1 | |
| SCHEMBL16876002 | 0.70 | HSD17B10 (0.49) | NAMPT | |
| SCHEMBL25941071 | 0.69 | TGFBR1 (0.55) | PDK2TGFBR1FFAR1FEN1 | |
| SCHEMBL27091168 | 0.68 | MAPK1 (0.47) | — | |
| SCHEMBL16703343 | 0.68 | HTR6 (0.44) | PDK2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021072330-A1 | GALNAC-TGFBR1 INHIBITOR CONJUGATES FOR THE TREATMENT OF LIVER DISEASES | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |